NCT01498445View on ClinicalTrials.gov

An Open-Label, Phase I/II Study of Two Different Schedules of Dasatinib (Sprycel) and Decitabine (Dacogen) Used in Combination for Patients With Accelerated or Blastic Phase Chronic Myelogenous Leukemia (Protocol CA180357)

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

June 12, 2012

Primary Completion Date

September 24, 2019

Study Completion Date

September 24, 2019

Conditions
Leukemia
Interventions
DRUG

Dasatinib

Starting Dose: 100 mg by mouth once daily of a 28 day cycle.

DRUG

Decitabine

Starting Dose (less intensive group) Schedule A: 10 mg/m2 by vein daily for 10 days of a 28 day cycle.

DRUG

Decitabine

Starting Dose (more intensive group) Schedule B: 20 mg/m2 by vein daily for 10 days of a 28 day cycle.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER